The 10th IAS Conference on HIV Science (IAS 2019) took place 21-24 July at the Centro Citibanamex in Mexico City. HPTN researchers presented study data during three symposia/satellite sessions, four oral presentations, and 13 poster presentations.
On Monday morning, 22 July, Dr. Connie Celum, HPTN 082 study chair, discussed primary results from the study during a satellite session on prevention solutions for the next generation. The session highlighted adolescent research in the NIH HIV/AIDS clinical trials networks (including the HPTN) and the Adolescent Medicine Trials Network. HPTN 082 data show pre-exposure prophylaxis (PrEP) use was high but waned after three months among the young African women enrolled in the study. Later in the morning,
Dr. Nyaradzo Mgodi, HPTN Executive Committee member, and Dr. Myron Cohen, HPTN co-principal investigator, participated in a symposia session on new prevention products. Dr. Mgodi reviewed advances in the field of broadly neutralizing antibodies, while Dr. Cohen talked about long-acting injectables for PrEP including rilpivirine (HPTN 076) and cabotegravir (HPTN 077, HPTN 083, HPTN 084).

HPTN 071 (PopART) researchers hosted a symposia session entitled “Towards Zero New HIV Infections: Lessons Learnt from the HPTN 071 (PopART) Trial.” The session featured presentations from Dr. Richard Hayes, HPTN 071 study chair, Dr. Sarah Fidler, HPTN 071 study co-chair, Dr. William Probert, an infectious disease modelling researcher, Dr. Katharina Hauck, a health economist, and Dr. Musonda Simwina, a senior social scientist and stakeholder and community engagement lead. New mathematical modelling and cost-effectiveness projections show the continuation of community-wide HIV testing and prompt initiation of treatment as delivered in the HPTN 071 (PopART) study in South Africa and Zambia could lead to substantial reductions in new HIV cases, be cost-effective, and help to achieve the UNAIDS 2030 targets. The session concluded with a panel discussion featuring Amb. Deborah Birx (PEPFAR), Dr. Marijke Wijroks (Global Fund), Solange Baptiste (International Treatment Preparedness Coalition), and Dr. Meg Doherty (WHO). Following a poster exhibition, the day ended with an oral abstract session featuring Dr. Chris Beyrer and his presentation of HPTN 078 primary results. Study findings show engaging disenfranchised men who have sex with men (MSM) living with HIV in the U.S. is possible, but the best way to help them achieve and maintain viral suppression is not yet known.

On Tuesday, 23 July, Dr. Michelle Andrasik discussed community engagement experiences from HVTN 703/HPTN 081 and HVTN 704/HPTN 085 (AMP). Following a poster exhibition, Dr. William Probert shared modelling and phylogenetics findings from the HPTN 071 (PopART) study. Also, Dr. Nomhle Khoza presented findings from HPTN 082 regarding the measurement of perceptions of sexual risk among adolescent girls and young women taking PrEP. Later, Dr. Marie Stoner discussed modelling combination interventions from HPTN 068, and Dr. Connie Celum explained PrEP adherence and the effect of drug level feedback among young African women in the trial.

The conference concluded on Wednesday, 24 July, with the third and final poster exhibition.
Representatives from the HPTN and HIV Vaccine Trials Network (HVTN), together with colleagues from the US National Institutes of Health and the AIDS Clinical Trials Group (ACTG) will visit Cape Town, South Africa, 6-7 August for a stakeholder symposium and protocol development meeting for HVTN 804/HPTN 095 (AMP Analytical Antiretroviral Treatment Interruption Study). Stakeholder symposium sessions will introduce and explore HIV remission research, explore bioethics, and community and clinical perspectives on HIV remission research and ART interruptions. The protocol development team will use information gained from the symposium for the development of HVTN 804/HPTN 095 to ensure cultural and scientific appropriateness.

HPTN 071 (PopART) study team members presented at the AIDS Impact conference in London (29-31 July). Drs. James Hargreaves, Anne Stangl, Graeme Hoddinott, and Virginia Bond, along with Bwalya Chiti and Lario Viljoen, presented results from the HPTN 071 (PopART) stigma ancillary study. The international behavioral and psychosocial science conference addresses issues related to HIV/AIDS prevention, treatment and care, focusing both globally and on specific communities and countries hardest hit by the HIV/AIDS epidemic.

Dr. Brandon Brown, HPTN Scholar and associate professor of social medicine, population, and public health at the University of California at Riverside, recently published an article in Science magazine about his experience with academic negotiation. He was also recently offered a grant by the Japan Association for Bioethics (JAB)-ASBH Fellowship Fund and will attend the 31st Annual JAB Conference on 7-8 December in Sendai, Japan to present a paper and chair a session. Dr. Brown was part of the 2015-2016 HPTN Domestic Scholars cohort, working with Dr. Tom Coates on HPTN 043.
Estelle Piwowar-Manning, MT, is the deputy director at the HPTN Laboratory Center and director of the Quality Assurance/Quality Control (QA/QC) core at Johns Hopkins University in Baltimore. She is a medical technologist specializing in immunology with more than 25 years’ experience in HIV diagnostics, Good Clinical Laboratory Practice, CLIA/ISO standards as well QA/QC at both domestic and international sites. Estelle oversees the LC QA core and is a protocol team member of several HPTN studies.

How did you first get involved with the HPTN?
I worked for Dr. Brooks Jackson, HPTN 027 U.S. protocol co-chair, at Case Western Reserve University and was supporting and supervising laboratory activities in Kampala, Uganda at both the CWRU/UCSF laboratory and the Joint Clinical Research Centre laboratory. I helped both laboratories set up CD4 testing as well as HIV ELISA and p24 Ag testing. When Dr. Jackson moved to become the director of clinical affairs in the Department of Pathology at Johns Hopkins University, I moved with him to Baltimore to supervise the new JHU ACTG processing lab as well as the Johns Hopkins Hospital HIV-related testing lab. I later got involved in overseeing the PACTG processing lab. It was around this time when the first round of HPTN studies was taking shape, so I have been involved from the start.
Hot Off The Press


What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at news@hptn.org.

Copyright © 2019 The HIV Prevention Trials Network, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.